Monoclonal antibodies (MAb) solutions are a major class of biopharmaceuticals with various applications. However, challenges such as a high viscosity at the required MAb concentrations need to be addressed at an early development stage.
Monoclonal antibodies are important biopharmaceuticals for treating diseases such as cancer, inflammation, allergies, infectious diseases and cardiovascular diseases. The challenge is, however, the low potency of MAb and the high viscosity of concentrated MAb solutions. Injection volumes bigger than 1.5 mL are not suitable for subcutaneous administration.
Due to the low potency, MAb solutions often need to be concentrated in order to cover the required dosage at a reasonable volume. But as a consequence viscosity is a technical issue for the stability and manufacturability of MAb solutions and negatively affects the usability for subcutaneous injection.
Download the Application Note to find out more.
IEA report shows nuclear sector booming despite costs
Delays, in the UK, over approval of nuclear, seem to be the major issue (such as for SMRs). The report is about market finance and does not address...